A Phase 1b Randomized, Controlled, Double-Blinded Dosage-Escalation Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkinabe Healthy Adults 18 to 45 Years of Age

BACKGROUND: Ad35.CS.01 is a pre-erythrocytic malaria candidate vaccine. It is a codon optimized nucleotide sequence representing the P. falciparum circumsporozoite (CS) surface antigen inserted in a replication deficient Adenovirus 35 backbone. A Phase 1a trial has been conducted in the USA in naïve...

Descripción completa

Detalles Bibliográficos
Autores principales: Ouédraogo, Alphonse, Tiono, Alfred B., Kargougou, Désiré, Yaro, Jean Baptiste, Ouédraogo, Esperance, Kaboré, Youssouf, Kangoye, David, Bougouma, Edith C., Gansane, Adama, Henri, Noelie, Diarra, Amidou, Sanon, Souleymane, Soulama, Issiaka, Konate, Amadou T., Watson, Nora L., Brown, Valerie, Hendriks, Jenny, Pau, Maria Grazia, Versteege, Isabella, Wiesken, Edison, Sadoff, Jerald, Nebie, Issa, Sirima, Sodiomon B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823848/
https://www.ncbi.nlm.nih.gov/pubmed/24244339
http://dx.doi.org/10.1371/journal.pone.0078679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823848/
https://www.ncbi.nlm.nih.gov/pubmed/24244339
http://dx.doi.org/10.1371/journal.pone.0078679

Ejemplares similares